Literature DB >> 8016873

Prostaglandin E plus famciclovir--a new concept for the treatment of severe hepatitis B after liver transplantation.

K H Böker1, B Ringe, M Krüger, R Pichlmayr, M P Manns.   

Abstract

New concepts for the treatment of hepatitis B in immunocompromised patients are urgently needed. We describe our first experience with the new antiviral agent famciclovir in combination with a short course of prostaglandin E in a patient with severe hepatitis B after liver transplantation. Initial treatment with prostaglandin E reduced the inflammatory activity, as measured by transaminase activities, but did not affect viral replication. Consecutive long-term treatment with famciclovir further normalized liver function and profoundly suppressed viral replication. HBeAg and HBV-DNA -PCR all became negative and only HBsAg persisted. Histology documented marked reduction of cellular infiltration. The patient completely recovered and is back to regular work as a teacher.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8016873

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

Review 1.  Treatment of chronic hepatitis B: new antiviral therapies.

Authors:  F Yao; R G Gish
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

Review 2.  Update on diagnosis, management, and prevention of hepatitis B virus infection.

Authors:  F J Mahoney
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

3.  Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.

Authors:  S K Ono-Nita; N Kato; Y Shiratori; K H Lan; H Yoshida; F J Carrilho; M Omata
Journal:  J Clin Invest       Date:  1999-06       Impact factor: 14.808

4.  Current Options for the Therapy of Chronic Hepatitis B Infection.

Authors:  Suzane Kioko Ono-Nita; Naoya Kato; Yasushi Shiratori; Masao Omata
Journal:  Curr Infect Dis Rep       Date:  2001-04       Impact factor: 3.725

5.  Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue.

Authors:  A J Nicoll; D L Colledge; J J Toole; P W Angus; R A Smallwood; S A Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

6.  Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo.

Authors:  E Lin; C Luscombe; D Colledge; Y Y Wang; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

Review 7.  Beneficial role of bioactive lipids in the pathobiology, prevention, and management of HBV, HCV and alcoholic hepatitis, NAFLD, and liver cirrhosis: A review.

Authors:  Undurti N Das
Journal:  J Adv Res       Date:  2018-12-21       Impact factor: 10.479

8.  Famciclovir (FAMVIR).

Authors:  S L Sacks
Journal:  Infect Dis Obstet Gynecol       Date:  1997
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.